Genomic Assays in Node Positive Breast Cancer Patients: A Review

Zerdan, Maroun Bou; Ibrahim, Maryam; Nakib, Clara El; Hajjar, Rayan; Assi, Hazem

doi:10.3389/fonc.2020.609100

Cited by 14 publications

(6 citation statements)

References 140 publications

(257 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, multigene expression profiles, such as Oncotype DX, MammaPrint, and Prosiga, have become widely used to predict the risk of recurrence and adjuvant chemotherapy benefits. 4 , 27 , 28 , 29 However, these genomic‐based classification applications are restricted in our developing countries because of the relatively higher price. On the other hand, the indications for these genetic tests are too broad, easily cause abuse, and bring unnecessary economic burdens.…”

Section: Discussionmentioning

confidence: 99%

“…[24][25][26] Currently, multigene expression profiles, such as Oncotype DX, MammaPrint, and Prosiga, have become widely used to predict the risk of recurrence and adjuvant chemotherapy benefits. 4,[27][28][29] However, these genomicbased classification applications are restricted in our developing countries because of the relatively higher price. On the other hand, the indications for these genetic tests are too broad, easily cause abuse, and bring unnecessary economic burdens.…”

Section: T a B L E 5 Associations Between Clinical And Pathological F...mentioning

confidence: 99%

See 1 more Smart Citation

The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score

et al. 2022

View full text Add to dashboard Cite

Background Breast cancer (BC) remains the leading cause of cancer‐related deaths worldwide. High recurrence risk Luminal BC receives adjuvant chemotherapy in addition to standard hormone therapy. Considering the heterogeneity of Luminal B BC, a more accurate classification model is urgently needed. Methods In this study, we retrospectively reviewed the data of 1603 patients who were diagnosed with HER2‐negative breast invasive ductal carcinoma. According to the expression level of PR and Ki‐67 index, the Luminal B (HER2‐negative) BCs were divided into three groups: ER+PR−Ki67 low (ER‐positive, PR‐negative, and Ki‐67 index <20%), ER+PR+Ki67 high (ER‐positive, PR‐positive, and Ki‐67 index ≥20%), and ER+PR−Ki67 high (ER‐positive, PR‐negative, and Ki‐67 index ≥20%). The cox proportional hazards regression model was used to evaluate the correlation between each variable and outcomes. Besides, discriminatory accuracy of the models was compared using the area under the receiver operating characteristic curve and log‐rank χ 2 value. Results The analysis results showed that there was a significant correlation between subtypes using this newly defined classification and overall survival ( p < 0.001) and disease‐free survival (DFS) ( p < 0.001). Interestingly, patients in the ER+PR−Ki67 high subgroup have the worst survival outcome in Luminal B (HER2‐negative) subtype, similar to Triple‐negative patients. Besides, the ER+PR+Ki67 high has worse 5‐year DFS compared with Luminal A group. There was a significant relationship between the regrouping subtype and the recurrence score index (RI) ( p < 0.001). Moreover, the results showed that patients in ER+PR–Ki67 high subtype were more likely to have high RI for distance recurrence (RI‐DR) and local recurrence (RI‐LRR). Our newly defined classification has a better discrimination ability to predict survival outcome and recurrence score of Luminal B (HER2‐negative) BC patients, which may help in clinical decision‐making for individual treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: T a B L E 5 Associations Between Clinical And Pathological F...mentioning

confidence: 99%

The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score

et al. 2022

View full text Add to dashboard Cite

show abstract

“…MammaPrint is able to identify more patients with ESBC who might not need chemotherapy. One study shows that the MammaPrint test may eventually be widely used to help make treatment decisions based on the risk of cancer recurrence within 10 years after diagnosis [ 56 ]. Another study by Cardoso F et al, who enrolled 1550 patients with ESBC, determined the genomic risk with the MammaPrint test, and compared their clinical risk in selected patients for ACT.…”

Section: Discussionmentioning

confidence: 99%

Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?

et al. 2022

View full text Add to dashboard Cite

Neoadjuvant chemotherapy (NACT) was developed with the aims of shrinking tumors or stopping cancer cells from spreading before surgery. Unfortunately, not all breast cancer patients will benefit from NACT, and thus, patients must weigh the risks and benefits of treatment prior to the initiation of therapy. Currently, the data for predicting the efficacy of NACT is limited. Molecular testing, such as Oncotype DX, MammaPrint, and Curebest 95GC, have been developed to assist which breast cancer patients will benefit from the treatment. Patients with an increased level of Human Leukocyte Antigen-DR isotype, tumor-infiltrating lymphocytes, Fizzy-related protein homolog, and a decreased level of tumor-associated macrophages appear to benefit most from NACT.

show abstract

“…MammaPrint® (Agilent), which was developed by the Dutch Cancer Institute in 2002, 6 was the first in vitro diagnostic multivariate index assay approved by the FDA in 2007. 39 The technique uses DNA microarrays to analyze primary tumors and applies supervised classification to identify gene expression signatures indicative of poor prognostic characteristics. Of the 25 000 human genes extracted, approximately 5000 were significantly regulated.…”

Section: -Gene Signature Test (Mammaprint®)mentioning

confidence: 99%

The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer

Chen

Fang

et al. 2022

Technol Cancer Res Treat

View full text Add to dashboard Cite

Breast cancer is a kind of malignant tumor that seriously endangers women's life and health. Once diagnosed, most patients will receive a combination of treatments to achieve a cure. However, breast cancer is a heterogeneous disease. Even with the same clinical stage and pathological features, its response to treatment and postoperative recurrence risk may still be completely different. With the advent of genomic assay, some patients with early-stage breast cancer who originally needed treatment can still achieve long-term disease-free survival without adjuvant chemotherapy, so as to achieve personalized and accurate treatment mode to a certain extent. In this paper, we reviewed the 5 most widely used and studied genomic panel technologies in breast cancer, namely Oncotype DX , MammaPrint , RecurIndex , PAM50, and EndoPredict , according to accessibility and availability. Based on the results of the completed or ongoing clinical studies, we summarized the origin, applicable population, and clinical efficacy of each detection method, and discussed the potential development prospect of detection technology in the future.

show abstract

Genomic Assays in Node Positive Breast Cancer Patients: A Review

Cited by 14 publications

References 140 publications

The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score

The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score

Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?

The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer

Contact Info

Product

Resources

About